S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
BABA   171.16 (-1.03%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
S&P 500   2,966.15 (-0.14%)
DOW   26,787.36 (-0.11%)
QQQ   191.09 (-0.01%)
AAPL   235.87 (-0.14%)
FB   183.28 (-0.49%)
MSFT   139.55 (-0.09%)
GOOGL   1,217.77 (+0.17%)
AMZN   1,736.43 (+0.26%)
CGC   18.86 (-2.93%)
NVDA   186.53 (+0.29%)
MU   44.86 (-0.53%)
BABA   171.16 (-1.03%)
GE   8.72 (-0.91%)
TSLA   256.96 (+3.66%)
AMD   30.53 (+2.62%)
T   37.47 (-0.29%)
F   8.82 (+0.46%)
ACB   3.51 (-4.62%)
PRI   121.47 (-0.18%)
NFLX   285.53 (+0.92%)
BAC   29.14 (+0.80%)
GILD   64.51 (+0.81%)
DIS   129.70 (-0.25%)
Log in

Zoetis Stock Price, News & Analysis (NYSE:ZTS)

$126.59
-1.88 (-1.46 %)
(As of 10/14/2019 04:00 PM ET)
Today's Range
$126.26
Now: $126.59
$129.00
50-Day Range
$119.82
MA: $125.38
$129.65
52-Week Range
$78.90
Now: $126.59
$130.09
Volume1.70 million shs
Average Volume2.10 million shs
Market Capitalization$60.45 billion
P/E Ratio40.44
Dividend Yield0.51%
Beta0.87
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites that include fleas, ticks, and worms. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP98978V10
Phone973-822-7000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.83 billion
Cash Flow$3.79 per share
Book Value$4.55 per share

Profitability

Net Income$1.43 billion

Miscellaneous

Employees10,000
Market Cap$60.45 billion
Next Earnings Date11/7/2019 (Confirmed)
OptionableOptionable

Receive ZTS News and Ratings via Email

Sign-up to receive the latest news and ratings for ZTS and its competitors with MarketBeat's FREE daily newsletter.


Zoetis (NYSE:ZTS) Frequently Asked Questions

What is Zoetis' stock symbol?

Zoetis trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZTS."

How often does Zoetis pay dividends? What is the dividend yield for Zoetis?

Zoetis declared a quarterly dividend on Thursday, October 3rd. Investors of record on Tuesday, October 22nd will be paid a dividend of $0.164 per share on Monday, December 2nd. This represents a $0.66 annualized dividend and a yield of 0.52%. The ex-dividend date of this dividend is Monday, October 21st. View Zoetis' Dividend History.

How will Zoetis' stock buyback program work?

Zoetis announced that its board has initiated a stock repurchase program on Wednesday, December 12th 2018, which allows the company to repurchase $2,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to repurchase up to 4.7% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board of directors believes its shares are undervalued.

How were Zoetis' earnings last quarter?

Zoetis Inc (NYSE:ZTS) issued its quarterly earnings data on Tuesday, August, 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.82 by $0.08. The business earned $1.55 billion during the quarter, compared to analyst estimates of $1.51 billion. Zoetis had a net margin of 22.74% and a return on equity of 72.86%. The firm's revenue for the quarter was up 9.3% compared to the same quarter last year. During the same period last year, the company earned $0.77 earnings per share. View Zoetis' Earnings History.

When is Zoetis' next earnings date?

Zoetis is scheduled to release their next quarterly earnings announcement on Thursday, November 7th 2019. View Earnings Estimates for Zoetis.

How can I listen to Zoetis' earnings call?

Zoetis will be holding an earnings conference call on Thursday, November 7th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What guidance has Zoetis issued on next quarter's earnings?

Zoetis issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $3.53-3.60 for the period, compared to the Thomson Reuters consensus estimate of $3.49. The company issued revenue guidance of $6.18-6.28 billion, compared to the consensus revenue estimate of $6.19 billion.

What price target have analysts set for ZTS?

15 Wall Street analysts have issued 12 month price objectives for Zoetis' shares. Their forecasts range from $86.00 to $145.00. On average, they expect Zoetis' share price to reach $124.40 in the next year. This suggests that the stock has a possible downside of 1.7%. View Analyst Price Targets for Zoetis.

What is the consensus analysts' recommendation for Zoetis?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zoetis in the last year. There are currently 6 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Zoetis.

Has Zoetis been receiving favorable news coverage?

News coverage about ZTS stock has been trending negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Zoetis earned a coverage optimism score of -2.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Zoetis.

Are investors shorting Zoetis?

Zoetis saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 4,420,000 shares, an increase of 30.8% from the August 30th total of 3,380,000 shares. Based on an average daily trading volume, of 1,890,000 shares, the short-interest ratio is presently 2.3 days. Approximately 0.9% of the shares of the company are short sold. View Zoetis' Current Options Chain.

Who are some of Zoetis' key competitors?

What other stocks do shareholders of Zoetis own?

Who are Zoetis' key executives?

Zoetis' management team includes the folowing people:
  • Mr. Juan Ramón Alaix, CEO & Director (Age 68)
  • Mr. Glenn C. David, Exec. VP & CFO (Age 47)
  • Dr. Catherine A. Knupp, Exec. VP and Pres of R&D (Age 58)
  • Mr. Clinton A. Lewis Jr., EVP and Grp Pres of Intl. Ops., Comm. Devp., Glbl Genetics, Aquatic Health & Human Medical Digs (Age 52)
  • Ms. Kristin C. Peck, Exec. VP and Group Pres of U.S. Operations, Bus. Devel. & Strategy (Age 48)

Who are Zoetis' major shareholders?

Zoetis' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Artemis Investment Management LLP (0.17%), Hexavest Inc. (0.08%), Gofen & Glossberg LLC IL (0.06%), Polaris Greystone Financial Group LLC (0.04%), Copper Rock Capital Partners LLC (0.04%) and Neville Rodie & Shaw Inc. (0.03%). Company insiders that own Zoetis stock include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Khosla Sanjay, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Institutional Ownership Trends for Zoetis.

Which institutional investors are selling Zoetis stock?

ZTS stock was sold by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Decatur Capital Management Inc., IMS Capital Management, Gofen & Glossberg LLC IL, Crossmark Global Holdings Inc., Neville Rodie & Shaw Inc., Everence Capital Management Inc. and Private Trust Co. NA. Company insiders that have sold Zoetis company stock in the last year include Catherine A Knupp, Clinton A Jr Lewis, Glenn David, Heidi C Chen, Juan Ramon Alaix, Kristin C Peck, Roman Trawicki, Roxanne Lagano and Willie M Reed. View Insider Buying and Selling for Zoetis.

Which institutional investors are buying Zoetis stock?

ZTS stock was purchased by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, State of Alaska Department of Revenue, Park National Corp OH, Pacer Advisors Inc., Hexavest Inc., Cypress Capital Group, Bath Savings Trust Co and Fulton Bank N.A.. View Insider Buying and Selling for Zoetis.

How do I buy shares of Zoetis?

Shares of ZTS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Zoetis' stock price today?

One share of ZTS stock can currently be purchased for approximately $126.59.

How big of a company is Zoetis?

Zoetis has a market capitalization of $60.45 billion and generates $5.83 billion in revenue each year. The company earns $1.43 billion in net income (profit) each year or $3.13 on an earnings per share basis. Zoetis employs 10,000 workers across the globe.View Additional Information About Zoetis.

What is Zoetis' official website?

The official website for Zoetis is http://www.zoetis.com/.

How can I contact Zoetis?

Zoetis' mailing address is 10 Sylvan Way, Parsippany NJ, 07054. The company can be reached via phone at 973-822-7000 or via email at [email protected]


MarketBeat Community Rating for Zoetis (NYSE ZTS)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  708 (Vote Outperform)
Underperform Votes:  429 (Vote Underperform)
Total Votes:  1,137
MarketBeat's community ratings are surveys of what our community members think about Zoetis and other stocks. Vote "Outperform" if you believe ZTS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ZTS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/14/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel